Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 767 participants.
Also called NCT03141073
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 767 participants
- Sponsor
- Registry
-
NCT03141073
-
- Other papers using this trial's data
- Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03141073. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-15 (actual); primary completion 2021-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- HMS5552
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hua Medicine Limited
- Collaborator
- Covance
Record details
- Record id
cardio:ct-nct03141073- Content hash
457c19dec539597e3d66a14b5a2833a39ec47738efcadb9d02f40b329f1a0f61